BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

694 related articles for article (PubMed ID: 23064955)

  • 21. Phase I study of a combination of s-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer.
    Ueda Y; Yamagishi H; Ichikawa D; Morii J; Koizumi K; Kakihara N; Shimotsuma M; Takenaka A; Yamashita T; Kurioka H; Nishiyama M; Morita S; Nakamura K; Sakamoto J
    Oncology; 2005; 69(3):261-8. PubMed ID: 16138002
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I/II trial of combination therapy with S-1 and weekly paclitaxel in patients with unresectable or recurrent gastric cancer.
    Inada S; Tomidokoro T; Fukunari H; Sato T; Hatano T; Nishimura A; Kawauchi Y; Nikkuni K; Shimizu T; Sato T; Yanagi M; Takahashi S; Yoshida H; Sugita M; Hayashi T
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):267-73. PubMed ID: 18379784
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A multicenter phase II study of biweekly paclitaxel and S-1 combination chemotherapy for unresectable or recurrent gastric cancer.
    Nakajo A; Hokita S; Ishigami S; Miyazono F; Etoh T; Hamanoue M; Maenohara S; Iwashita T; Komatsu H; Satoh K; Aridome K; Morita S; Natsugoe S; Takiuchi H; Nakano S; Maehara Y; Sakamoto J; Aikou T;
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1103-9. PubMed ID: 18317763
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase II study of biweekly S-1 and paclitaxel (SPA) as first-line chemotherapy in patients with metastatic or advanced gastric cancer.
    Jiang H; Qian J; Zhao P; Zhang X; Zheng Y; Mao C; Zheng Y; Chen L; Wang Y; Mou H; Fang W; Teng L; Xu N
    Cancer Chemother Pharmacol; 2015 Jul; 76(1):197-203. PubMed ID: 26013324
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.
    Kim JA; Lee J; Han B; Park SH; Park JO; Park YS; Lim HY; Kang WK
    Cancer Chemother Pharmacol; 2011 Jul; 68(1):177-84. PubMed ID: 20878159
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trastuzumab combined with docetaxel-based regimens in previously treated metastatic gastric cancer patients with HER2 over-expression.
    Dai GH; Shi Y; Chen L; Lv YL; Zhong M
    Hepatogastroenterology; 2012; 59(120):2439-44. PubMed ID: 22534547
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Salvage chemotherapy with docetaxel and epirubicin for advanced/metastatic gastric cancer.
    Lim JY; Cho JY; Paik YH; Lee DK; Lee SI; Park HJ; Lee SJ; Lee KS; Yoon DS; Choi SH
    Oncology; 2007; 73(1-2):2-8. PubMed ID: 18332648
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Feasibility study of S-1 and intraperitoneal docetaxel combination chemotherapy for gastric cancer with peritoneal dissemination.
    Fujiwara Y; Nishida T; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Yamamoto K; Moon JH; Mori M; Doki Y
    Anticancer Res; 2010 Apr; 30(4):1335-9. PubMed ID: 20530449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dose-finding study of docetaxel, oxaliplatin, and S-1 for patients with advanced gastric cancer.
    Zang DY; Yang DH; Kim MJ; Jang KM; Hwang SW; Yoo KS; Han T; Kim HY; Kim HJ; Kwon JH; Song HH; Park S; Jung JY; Kim HS; Kim JH
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):877-83. PubMed ID: 19190908
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II study of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin as first-line chemotherapy in patients with advanced gastric cancer.
    Wang F; Wang Z; Zhou N; An X; Xu R; He Y; Li Y
    Am J Clin Oncol; 2011 Aug; 34(4):401-5. PubMed ID: 21791984
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oxaliplatin combined with continuous infusion of 5-fluorouracil as first-line chemotherapy in patients with metastatic or recurrent gastric adenocarcinoma.
    Lim JY; Cho JY; Oh KJ; Choi SH; Lee SI; Jeung HC
    Chemotherapy; 2009; 55(4):200-6. PubMed ID: 19451710
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intraperitoneal docetaxel combined with S-1 for advanced gastric cancer with peritoneal dissemination.
    Fujiwara Y; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Mori M; Doki Y
    J Surg Oncol; 2012 Jan; 105(1):38-42. PubMed ID: 21882194
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I/II study of a combination of docetaxel, capecitabine, and cisplatin (DXP) as first-line chemotherapy in patients with advanced gastric cancer.
    Kang YK; Ryu MH; Yoo C; Chang HM; Yook JH; Oh ST; Kim BS; Kim TW
    Cancer Chemother Pharmacol; 2011 Jun; 67(6):1435-43. PubMed ID: 20811894
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Feasibility study of S-1 plus weekly docetaxel combined with concurrent radiotherapy in advanced gastric cancer refractory to first-line chemotherapy.
    Fujitani K; Tsujinaka T; Yamasaki H; Hirao M; Yoshida K; Kurokawa Y
    Anticancer Res; 2009 Aug; 29(8):3385-91. PubMed ID: 19661361
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination chemotherapy of S-1 and low-dose twice-weekly cisplatin for advanced and recurrent gastric cancer in an outpatient setting: a retrospective study.
    Tsuji A; Shima Y; Morita S; Uchida M; Okamoto K; Morita M; Horimi T; Shirasaka T
    Anticancer Res; 2008; 28(2B):1433-8. PubMed ID: 18505092
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A multicenter, phase I dose-escalating study of docetaxel, cisplatin and S-1 for advanced gastric cancer (KDOG0601).
    Nakayama N; Koizumi W; Sasaki T; Higuchi K; Tanabe S; Nishimura K; Katada C; Nakatani K; Takagi S; Saigenji K
    Oncology; 2008; 75(1-2):1-7. PubMed ID: 18719348
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High intratumoral dihydropyrimidine dehydrogenase mRNA levels in pancreatic cancer associated with a high rate of response to S-1.
    Kuramochi H; Hayashi K; Uchida K; Nakajima G; Hatori T; Danenberg KD; Danenberg PV; Yamamoto M
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):85-9. PubMed ID: 18309485
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Docetaxel plus oxaliplatin in combination with capecitabine as first-line treatment for advanced gastric cancer.
    Amarantidis K; Xenidis N; Chelis L; Chamalidou E; Dimopoulos P; Michailidis P; Tentes A; Deftereos S; Karanikas M; Karayiannakis A; Kakolyris S
    Oncology; 2011; 80(5-6):359-65. PubMed ID: 21811088
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I study of combination therapy with S-1 and weekly docetaxel for advanced gastric cancer.
    Ozaki T; Tamura K; Satoh T; Kurata T; Shimizu T; Miyazaki M; Okamoto I; Nakagawa K; Fukuoka M
    Anticancer Res; 2007; 27(4C):2657-65. PubMed ID: 17695429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modified docetaxel-cisplatin in combination with capecitabine as first-line treatment in metastatic gastric cancer. a phase II study.
    Polyzos A; Felekouras E; Karatzas T; Griniatsos J; Dimitroulis D; Polyzos K; Kontzoglou K; Mantas D; Karavokyros J; Nikiteas N; Tsavaris N; Syrigos K; Vafiadis I
    Anticancer Res; 2012 Sep; 32(9):4151-6. PubMed ID: 22993377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.